Cellular Biomedicine Group Inc. (CBMG) 5.3500

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellular Biomedicine Group Inc. (CBMG) 5.3500 $CBMG Cellular Biomedicine Group Releases Positive Results From Phase I Clinical Trial for Hepatocellular Carcinoma GlobeNewswire - Mon Mar 24, 11:53AM CDT Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy GlobeNewswire - Mon Mar 17, 12:28PM CDT Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma. Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA) GlobeNewswire - Mon Feb 24, 10:15AM CST Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe. Cellular Biomedicine Group to Present at New York Stem Cell Summit GlobeNewswire - Wed Feb 05, 6:24PM CST Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast. Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair GlobeNewswire - Fri Jan 03, 11:45AM CST Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer PR Newswire - Fri Dec 13, 2:33PM CST Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. Cellular Biomedicine Group to Present "Expedited Development of Cellular Medicine" at Hong Kong Biotech Horizons Conference GlobeNewswire - Tue Nov 19, 12:05AM CST Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Wei (William) Cao, Ph.D., B.M., Chief Executive Officer, will present at the Hong Kong Biotech Horizons Conference on Thursday, November 21, 2013, at 11:15 a.m. at the Charles K. Kao Auditorium, Hong Kong Science and Technology Park, Hong Kong. Cellular Biomedicine Group Announces Adjournment of Its Annual Shareholder Meeting PR Newswire - Sat Nov 09, 4:55AM CST Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today convened the annual meeting of its shareholders. Because a quorum was not achieved by shares present at the meeting in person or by proxy, the shareholder meeting was adjourned to a later date as to be determined by the board of directors of the Company. The board of directors has fixed the close of business on November 18, 2013 as the record date for the determination of stockholders entitled to notice of and to vote at the annual meeting. New proxy materials will be distributed to all the shareholders. Management of the Company is confident that a quorum will be achieved in the re-convened meeting. Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting PR Newswire - Thu Nov 07, 1:45PM CST Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today reminded all its shareholders that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder of record. Cellular Biomedicine Group Receives Approval for Phase IIb Clinical Trial of ReJoin(TM) for Treatment of Knee Osteoarthritis (KOA) PR Newswire - Tue Nov 05, 10:36AM CST Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin(TM), a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) ReJoin(TM) formula in order to reduce inflammation and repair damaged joint cartilage. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA) PR Newswire - Fri Nov 01, 9:01AM CDT Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin(TM), a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License PR Newswire - Wed Oct 30, 8:01AM CDT Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal(TM) adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These two products, when used together, allow for safe and contaminant-free isolation of one million Vascular Stromal Cells per 1 mL of adipose tissue in as little as sixty minutes. The potential clients for both products are cosmetic clinics, research institutions, sports medicine departments and veterinarian clinics. Cellular Biomedicine Group calls for General Annual Shareholder Meeting on November 08, 2013 PR Newswire - Fri Oct 25, 9:08AM CDT Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder of record. Cellular Biomedicine Group Appoints Three Independent Directors to the Board PR Newswire - Mon Oct 14, 8:44AM CDT Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced that the Board of the Company has appointed three new independent directors to the Board, namely, Leo Dembinski, David Bolocan and Jeff Auerbach. Cellular Biomedicine Group Announces Change of Auditor PR Newswire - Wed Sep 11, 8:28AM CDT Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO") as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC"). Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA) PR Newswire - Fri Sep 06, 6:00AM CDT Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer PR Newswire - Thu Aug 22, 10:48AM CDT Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights PR Newswire - Fri Aug 16, 10:17AM CDT Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a developer of proprietary cell therapies for the treatment of degenerative diseases and cancers, this week reported financial results and business highlights for the quarter and six months ended June 30, 2013. CRWEPRESSRELEASE Daily Stock Watch Harris & Harris Group, Inc., (NASDAQ:TINY), Crown Equity Holdings Inc. (OTCQB:CRWE), and Cellular Biomedicine Group (OTCQB:CBMG) WorldStockWire - Tue Jul 30, 11:00AM CDT CRWEpressrelease.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on: Cellular Biomedicine Group Completes Enrollment in Phase I Clinical Trial for Knee Osteoarthritis PR Newswire - Mon Jul 22, 9:25AM CDT Cellular Biomedicine Group (OTCQB:CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 362

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 39

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 583

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Sentry Insurance Company Announces Strategic Acquisition Plans

Updated Category News Views 205

Insights into Sentry Insurance Company's Acquisition Strategy OLDWICK, N.J.--AM Best has announced that the Credit Ratings of Sentry Insurance Company, along with its subsidiaries—collectively known as Sentry—will stay stable after the recent news of their acquisition of The General from American Family Insurance Group. This deal includes Permanent General Assurance...

Continue Reading
Growth Outlook for the Automotive Horn System Market

Updated Category News Views 165

Overview of the Automotive Horn System Market Wilmington, Delaware - A recent market analysis reveals a significant shift in the automotive horn system industry. The report estimates that the market, currently valued at $0.7 billion, is projected to grow to $1.8 billion by the end of the forecast period in 2033, achieving an impressive compound annual growth rate (CAGR)...

Continue Reading
Payoneer Completes Warrant Purchase Offer and Amendments

Updated Category News Views 105

Payoneer Completes Warrant Purchase Offer and Consent Solicitation Payoneer Global Inc. (NASDAQ: PAYO), a financial technology company serving businesses worldwide, has completed its cash offer to buy outstanding Warrants at $0.78 each. The move is designed to simplify Payoneer’s capital structure and give warrant holders a clear cash alternative, while keeping the...

Continue Reading
The Aesthetic Medicine Market's Future: Key Trends to Watch

Updated Category News Views 251

Sales Expectations for the Aesthetic Medicine Market The global aesthetic medicine market was estimated at US$ 83.12 billion recently, with projections indicating a remarkable potential to rise to US$ 233.67 billion by the year 2033. This growth is anticipated at a compound annual growth rate (CAGR) of 12.17% from 2025 through to 2033. Impact of Technological Innovations...

Continue Reading
Bauducco's Florida Expansion Boosts U.S. Manufacturing

Updated Category News Views 74

New Facility Marks a Strategic Shift for Bauducco Imagine three generations crafting baked goods, and then picture this: Bauducco, the Brazilian icon for snacks like wafer cookies and Panettone, boldly stepping onto the U.S. manufacturing stage. They have just swung wide the doors of their largest stateside factory, right in Zephyrhills, Florida. They're not here to...

Continue Reading